Related Experiment Video
Updated: Jan 30, 2026
Orthotopic Mouse Model of Colorectal Cancer
Published on: December 4, 2007
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
David J Hermel1, Darren Sigal2
1Department of Medicine, University of Southern California, 2020 Zonal Avenue, Los Angeles, CA 90033, USA. david.hermel@med.usc.edu.
Abstract:
Checkpoint inhibitor therapy has introduced a revolution in contemporary anticancer therapy. It has led to dramatic improvements in patient outcomes and has spawned tremendous research into novel immunomodulatory agents and combination therapy that has changed the trajectory of cancer care. However, clinical benefit in patients with colorectal cancer has been generally limited to tumors with loss of mismatch repair function and those with specific germline mutations in the DNA polymerase gene. Unfortunately, tumors with these specific mutator phenotypes are in the minority. Recent pre-clinical and clinical studies have begun to reveal encouraging results suggesting that checkpoint inhibitor therapy can be expanded to an increasing number of colorectal tumors with microsatellite stability and the absence of traditional predictive biomarkers of checkpoint inhibitor response. These studies generally rely on combinations of checkpoint inhibitors with chemotherapy, molecular targeted therapy, radiation therapy, or other novel immunomodulatory agents. This article will review the most current data in microsatellite stable colorectal cancer.
Insights
Checkpoint inhibitor therapy shows promise beyond specific genetic markers in colorectal cancer. Emerging research explores combinations to expand treatment benefits to microsatellite stable tumors.
Area of Science:
- Oncology
- Immunotherapy
- Colorectal Cancer Research
Background:
- Checkpoint inhibitor therapy has revolutionized cancer treatment, improving patient outcomes.
- Clinical benefit in colorectal cancer is currently limited to tumors with mismatch repair deficiency or specific DNA polymerase gene mutations.
- These specific tumor subtypes represent a minority of colorectal cancer cases.
Purpose of the Study:
- To review current data on expanding checkpoint inhibitor therapy to microsatellite stable colorectal cancer.
- To explore novel combination strategies for treating colorectal tumors lacking traditional predictive biomarkers.
Main Methods:
- Review of recent pre-clinical and clinical studies.
- Analysis of combination therapies involving checkpoint inhibitors with chemotherapy, targeted therapy, radiation, or other immunomodulatory agents.
Main Results:
- Encouraging results suggest checkpoint inhibitor therapy can be effective in microsatellite stable colorectal tumors.
- Combination strategies are showing promise in overcoming resistance and expanding treatment eligibility.
Conclusions:
- Checkpoint inhibitor therapy holds potential for a broader range of colorectal cancer patients.
- Further research into combination therapies is crucial for enhancing clinical benefit in microsatellite stable disease.
Related Concept Videos
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
01:27Emerging Adulthood
00:46Feedback Inhibition
01:30Introduction Cardiac Emergencies
01:30Enzyme Inhibition
02:34Inhibition of Cdk Activity